ivermectin vs. placebo - COVID 19 outpatients low risk of bias
- inconclusive results for: hospitalizations or deaths; improvement in time to recovery
infliximab vs. placebo - COVID-19 severe or critically NA risk of bias
not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed.
risk of bias not assessable
hight dose vitamin D vs. Vitamin D - COVID-19 mild to moderate high risk of bias
- inconclusive results for: 14-day overall mortality; 28-days overall deaths
abatacept vs. placebo - COVID-19 severe or critically NA risk of bias
not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed.
risk of bias not assessable
Conclusive (statistically conclusive): statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error, does not take into account the risk of bias; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
|
|
|
-
About
-
Our approach
-
Credits
-
RSS
Made with in Lyon
-
Contact us
-
Privacy policy
-
